Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: Targeting VEGF-VEGFR signaling

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Deep, Gagan ^a,b   Gangar, Subhash Chander ^a   Rajamanickam, Subapriya ^a   Raina, Komal ^a   Gu, Mallikarjuna ^a   Agarwal, Chapla ^a,b   Oberlies, Nicholas H ^c   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; FLAVONOLIGNAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOSILYBIN A; ISOSILYBIN B; NESTIN; PROTEIN KINASE B; SILYBIN A; SILYBIN B; SILYBUM MARIANUM EXTRACT; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; DRUG DERIVATIVE; SILIBININ; SILYMARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AORTA; APOPTOSIS; ARTICLE; BLOOD VESSEL; CANCER INHIBITION; CAPILLARY TUBE; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CELL LINE; CHEMISTRY; DRUG SCREENING; NUDE MOUSE; PROSTATE TUMOR; SILYBUM MARIANUM; TUMOR CELL LINE;

MUS; SILYBUM MARIANUM;

ANIMALS; CELL LINE; CELL LINE, TUMOR; FLAVONOLIGNANS; HUMANS; MALE; MICE; MICE, NUDE; MILK THISTLE; PROSTATIC NEOPLASMS; SILYMARIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859721350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034630     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Hanahan D, Folkman J, (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
3. Naumov GN, Akslen LA, Folkman J, (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5: 1779-1787.
4. Menakuru SR, Brown NJ, Staton CA, Reed MW, (2008) Angiogenesis in pre-malignant conditions. Br J Cancer 99: 1961-1966.
5. Bergers G, Benjamin LE, (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
6. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM, (2001) Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61: 2736-2743.
7. Georgiou HD, Namdarian B, Corcoran NM, Costello AJ, Hovens CM, (2008) Circulating endothelial cells as biomarkers of prostate cancer. Nat Clin Pract Urol 5: 445-454.
8. Li H, Raia V, Bertolini F, Price DK, Figg WD, (2008) Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int 101: 884-888.
9. Li Y, Cozzi PJ, (2010) Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev 30: 23-66.
10. Yu EM, Jain M, Aragon-Ching JB, (2010) Angiogenesis inhibitors in prostate cancer therapy. Discov Med 10: 521-530.
11. George D, Moul JW, (2011) Emerging treatment options for patients with castration-resistant prostate cancer. Prostate.
12. Folkman J, (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
13. Folkman J, (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
14. Folkman J, (2006) Angiogenesis. Annu Rev Med 57: 1-18.
15. Cook KM, Figg WD, (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60: 222-243.
16. Samant RS, Shevde LA, (2011) Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2: 122-134.
17. Cao Y, (2009) Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2: re1.
18. Mulder K, Scarfe A, Chua N, Spratlin J, (2011) The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opin Biol Ther 11: 405-413.
19. Blanchet B, Billemont B, Barete S, Garrigue H, Cabanes L, et al. (2010) Toxicity of sorafenib: clinical and molecular aspects. Expert Opin Drug Saf 9: 275-287.
20. Deep G, Oberlies NH, Kroll DJ, Agarwal R, (2007) Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis 28: 1533-1542.
21. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, et al. (2005) Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 65: 4448-4457.
22. Deep G, Oberlies NH, Kroll DJ, Agarwal R, (2008) Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int J Cancer 123: 41-50.
23. Kroll DJ, Shaw HS, Oberlies NH, (2007) Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 6: 110-119.
24. Deep G, Oberlies NH, Kroll DJ, Agarwal R, (2008) Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene 27: 3986-3998.
25. Deep G, Raina K, Singh RP, Oberlies NH, Kroll DJ, et al. (2008) Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: Comparison with silymarin and silibinin. Int J Cancer 123: 2750-2758.
26. Graf TN, Wani MC, Agarwal R, Kroll DJ, Oberlies NH, (2007) Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention. Planta Med 73: 1495-1501.
27. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, et al. (2006) Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 98: 846-855.
28. Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R, (2007) Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 28: 2567-2574.
29. Gu M, Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R, (2007) Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res 67: 3483-3491.
30. Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R, (2005) Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy. Oncogene 24: 1188-1202.
31. Deep G, Gangar SC, Agarwal C, Agarwal R, (2011) Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) 4: 1222-1232.
32. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R, (2006) Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25: 1053-1069.
33. Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, et al. (2009) Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther 8: 2366-2374.
34. Zi X, Feyes DK, Agarwal R, (1998) Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res 4: 1055-1064.
35. Pang X, Yi Z, Zhang X, Sung B, Qu W, et al. (2009) Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69: 5893-5900.
36. Takenaga K, (2011) Angiogenic signaling aberrantly induced by tumor hypoxia. Front Biosci 16: 31-48.
37. Liao D, Johnson RS, (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26: 281-290.
38. Airley RE, Mobasheri A, (2007) Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53: 233-256.
39. Hua K, Din J, Cao Q, Feng W, Zhang Y, et al. (2009) Estrogen and progestin regulate HIF-1alpha expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway. Oncol Rep 21: 893-898.
40. Kim D, Dan HC, Park S, Yang L, Liu Q, et al. (2005) AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 10: 975-987.
41. Hsieh AC, Truitt ML, Ruggero D, (2011) Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer 105: 329-336.
42. Patan S, (2004) Vasculogenesis and angiogenesis. Cancer Treat Res 117: 3-32.
43. Saunders WB, Bohnsack BL, Faske JB, Anthis NJ, Bayless KJ, et al. (2006) Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3. J Cell Biol 175: 179-191.
44. Bicknell R, Harris AL, (2004) Novel angiogenic signaling pathways and vascular targets. Annu Rev Pharmacol Toxicol 44: 219-238.
45. Tosetti F, Ferrari N, de Flora S, Albini A, (2002) Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16: 2-14.
46. Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB, (2006) Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26: 4457-4498.
47. Kim NC, Graf TN, Sparacino CM, Wani MC, Wall ME, (2003) Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem 1: 1684-1689.